Health Catalyst (NASDAQ:HCAT) Given Overweight Rating at Cantor Fitzgerald

Health Catalyst (NASDAQ:HCAT)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $16.00 target price on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 84.12% from the stock’s current price.

Several other brokerages have also issued reports on HCAT. JPMorgan Chase & Co. lifted their price target on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Evercore ISI reduced their price objective on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 9th. Piper Sandler reduced their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 26th. Finally, Stephens reduced their price objective on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Health Catalyst presently has a consensus rating of “Moderate Buy” and an average target price of $11.42.

Health Catalyst Stock Performance

Shares of HCAT opened at $8.69 on Friday. Health Catalyst has a 52-week low of $5.42 and a 52-week high of $11.41. The business’s fifty day moving average is $7.29 and its 200-day moving average is $6.91. The firm has a market cap of $513.01 million, a price-to-earnings ratio of -4.70 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The company had revenue of $75.90 million for the quarter, compared to analyst estimates of $74.96 million. During the same quarter last year, the company posted ($0.21) EPS. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. As a group, research analysts forecast that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other Health Catalyst news, COO Daniel Lesueur sold 5,208 shares of Health Catalyst stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $6.15, for a total transaction of $32,029.20. Following the transaction, the chief operating officer now directly owns 155,215 shares of the company’s stock, valued at approximately $954,572.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Daniel Lesueur sold 5,208 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $6.15, for a total value of $32,029.20. Following the transaction, the chief operating officer now directly owns 155,215 shares of the company’s stock, valued at approximately $954,572.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,361 shares of company stock valued at $248,033. 2.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC lifted its stake in shares of Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after purchasing an additional 3,221,408 shares during the period. Millennium Management LLC lifted its stake in shares of Health Catalyst by 96.3% in the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after purchasing an additional 1,184,131 shares during the period. Primecap Management Co. CA raised its stake in Health Catalyst by 14.7% during the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock worth $15,205,000 after buying an additional 305,079 shares during the period. Daventry Group LP raised its stake in Health Catalyst by 3.9% during the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after buying an additional 84,178 shares during the period. Finally, Nepsis Inc. raised its stake in Health Catalyst by 8.3% during the 2nd quarter. Nepsis Inc. now owns 1,253,080 shares of the company’s stock worth $8,007,000 after buying an additional 95,686 shares during the period. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.